The pan-cancer methylation product jointly developed by Benchmark Medical and Twist Bioscience is launched globally

Guangzhou, October 11, 2021/PRNewswire/ --- jointly developed by AnchorDx and the famous American genetic company Twist Bioscience (Twist, NASDAQ: TWST, hereinafter referred to as "Twist") Methylated library preparation for pan-cancer species research and targeted enrichment NGS sequencing product-TopVest-benchmark methylated pan-cancer detection (hereinafter referred to as "methylated pan-cancer detection product") in September It will be launched globally on the 24th (US time)

This methylated pan-cancer detection product is a technical achievement jointly developed by Benchmark Medical and Twist in the past two years.

Dr.

Dr.

Benchmark Medical has signed a product cooperative marketing agreement with Twist, and will jointly carry out marketing and promotion work in the global methylation research service field, so that advanced technology can be fully applied to tumor screening and diagnosis, and to promote a higher level of global tumor precision medicine.

Twist news link: https://investors.

About benchmark medical

Leading precision medicine, benefiting thousands of households

Benchmark Medical was established in 2015.

Benchmark Medical is the first company in China to use ctDNA methylation high-throughput sequencing technology for early cancer diagnosis, and has independently constructed the world's largest database of early cancer methylation in the Chinese population

About Twist Bioscience

Twist Bioscience is a leading and fast-growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to promote the industrialization of bioengineering

Twist Bioscience's legal statement regarding forward-looking statements

This press release contains forward-looking statements

Source: Benchmark Medical AnchorDx